11 Weiner AL, Vieira L , Bayer MJ. Ketamine abusers presenting to the emergency department. J Emerg Med, 2000,18(4): 447-451.
12 Risner ME. Intravenous self-administration of PCP and related compounds in the dog. J Pharmacol Exp Ther, 1982,221(3): 637-644.
13 Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsy_chopharmacology, 1995, 13(1): 9-19.
14 Trujillo KA. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence (Review). Neuropsychopharmacology, 1995, 13(4): 301-307.
15 Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. medication development issues for opiate addiction(Review). Neuropsychopharmacol_ogy, 1995, 13(4): 269-293.
16 Weir E. Raves: a review of the culture, the drugs and the prevention of harm. CAMJ, 2000, 162(13): 1843-1848.
17 Gorman EM , Carroll RT. Substance abuse and HIV. J Assoc Nurses AIDS Care, 2000, 11(2): 51-62.